Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Paliperidone ER Outcomes Study of Schizophrenia Patients in Typical Clinical Practice (The POST Study).

Next Previous
X
Search
Trial Profile

The Paliperidone ER Outcomes Study of Schizophrenia Patients in Typical Clinical Practice (The POST Study).

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paliperidone (Primary) ; Aripiprazole; Olanzapine; Quetiapine; Risperidone; Ziprasidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms POST
  • Sponsors Ortho-McNeil

    • Most Recent Events

    • 01 May 2012 Actual patient number is 43 according to ClinicalTrials.gov.
    • 01 May 2012 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
    • 14 Dec 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top